Merck Obtains Japanese Approval For Januvia Use With Insulin
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Merck, Sharp & Dohme announced the approval of Januvia (sitagliptin) in combination use with insulin for type 2 diabetes